Please login to the form below
Triple negative breast cancer
This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... TNBC is an aggressive and hard-to-treat subtype of
Latest news
-
Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial
The HER-Vaxx jab is a B-cell activating cancer immunotherapy designed to target tumours that overexpress the HER2/neu receptor in gastric, breast, ovarian, lung and pancreatic cancers. ... Elsewhere in Imugene’s pipeline are a phase 1 triple negative
-
New trial data for Keytruda in triple-negative breast cancer
triple-negative breast cancer (TNBC) following a recent US Food and Drug Administration (FDA) rejection in this indication. ... TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide,
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics is also developing a potential preclinical therapeutic in-house – ENV-0205 – for the treatment of triple-negative breast cancer (TNBC). ... This programme came from Envisagenics’ identification of a splicing error that occurs in TNBC,
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... Triple negative breast cancer is known to be particularly aggressive and fast growing, and after treatment the risk of recurrence is faster and higher than in any other
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O’Day, chairman and chief executive officer, Gilead Sciences.
Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial
New trial data for Keytruda in triple-negative breast cancer
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
More from news
Approximately 8 fully matching, plus 72 partially matching documents found.
Latest Intelligence
-
Patient diversity in clinical trials needs to be centre stage
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
-
Cortellis Drugs to Watch in 2020 report
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
-
Pharma deals during February 2014
awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple
Patient diversity in clinical trials needs to be centre stage
Cortellis Drugs to Watch in 2020 report
Deal Watch February 2017
Pharma deals during February 2014
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital project manager
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- EU approves bluebird bio’s CALD gene therapy Skysona
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Onyx Health Launch Creative Studio After Record Year
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
- Positive prospects for pharma in Latin America
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Biosimilars in China
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
